Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSURE-AF
2008-003698-42Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atecegatran metoxil in Atrial fibrillation (AFib) (2 arms), sponsored by AstraZeneca. Primary endpoint: Stroke or systemic embolic event. Started Sep 2008; status: terminated.
02
Drugs
atecegatran metoxil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2008-003698-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003698-42.